Stock Market News
Diurnal secures Japanese patents and aims for further international commercialisation
Specialty pharmaceutical company Diurnal has secured two Japanese composition of matter patents for new products, it announced on Thursday.
The patents are for Diurnal's Alkindi product, a treatment for adrenal insufficiency in paediatric and elderly adult patients now protected until 2032, and its Chronocort product, giving the company's modified release hydrocortisone formulation in market protection until 2033.
Martin Whitaker, chief executive of Diurnal, said: "Japan is a significant potential market for both Alkindi and Chronocort. We are therefore delighted that these patents have proceeded to grant and will create the cornerstone of our strong exclusivity position in this territory."
The company's UK and US variants of the patents have already been granted.
"We will now look to secure a local partner, in line with our commercialisation strategy outside of the US and Europe, and will liaise with local regulatory authorities to determine the clinical studies that will be required for approval," said Whitaker.
Diurnal is a Cardiff-based company, dedicated to auctioning high-quality hormone therapeutics to assist with lifelong treatment for rare and chronic endocrine conditions such as congenital adrenal hyperplasia, hypothyroidism and adrenal insufficiency.
As of 0848 GMT, Diurnal shares were up 1.69% at 180.50p.
The patents are for Diurnal's Alkindi product, a treatment for adrenal insufficiency in paediatric and elderly adult patients now protected until 2032, and its Chronocort product, giving the company's modified release hydrocortisone formulation in market protection until 2033.
Martin Whitaker, chief executive of Diurnal, said: "Japan is a significant potential market for both Alkindi and Chronocort. We are therefore delighted that these patents have proceeded to grant and will create the cornerstone of our strong exclusivity position in this territory."
The company's UK and US variants of the patents have already been granted.
"We will now look to secure a local partner, in line with our commercialisation strategy outside of the US and Europe, and will liaise with local regulatory authorities to determine the clinical studies that will be required for approval," said Whitaker.
Diurnal is a Cardiff-based company, dedicated to auctioning high-quality hormone therapeutics to assist with lifelong treatment for rare and chronic endocrine conditions such as congenital adrenal hyperplasia, hypothyroidism and adrenal insufficiency.
As of 0848 GMT, Diurnal shares were up 1.69% at 180.50p.
Related share prices |
---|
Diurnal Group (DNL) share price |
Stock News headlines are gathered from financial news sources around the web. Views and opinions on each item are from their respective authors and website. They are not opinions of LiveCharts.co.uk
Get a free widget for your website with our latest headlines.
You can now add our live prices and new headlines to your website.The news widget features quotes for Oil prices, spot Gold price and Indices plus a choice of news channel for healines.
Top Shares pages
- Share price quotes
- Share charts
- Share watch list
- Company Results Calendar
- Top Large UK Shares
- UK Market Sectors
- Stock market news
- Company news
- Share tips
- A-Z company search
More share features
POPULAR Share Prices
- Royal Mail share price
- Lloyds share price
- HSBC share price
- Barclays share price
- Prudential share price
- Santander share price
- NEXT share price
- Diageo share price
- BP share price
- Vodafone share price
- British Airways
- Centrica share price
- Tesco share price
- Taylor Wimpey Share Price
- National Grid
- GKP Share Price
- Marks and Spencer
- Rolls Royce
- Rio Tinto
- THG Share Price
- Aviva Share Price
- Boil Share price
- Easyjet Share Price
- Genedrive Share Price
- SSE Share Price
- IAG Share Price
- Boohoo share price
- HE1 share price
- AVCT share price
- BOOM share price